With its headquarters located in Mumbai, Glenmark Pharmaceuticals Limited is a multinational pharmaceutical firm based in India. Glenmark Pharmaceuticals Ltd. is a multinational pharmaceutical firm focused on research that operates in the OTC, specialty, and generic markets. Gracias Saldanha established Glenmark Pharmaceuticals in 1977 as a producer of active pharmaceutical ingredients and generic medications.
Glenmark Pharmaceuticals – Quick Overview
| Particular | Details |
| Company Name | Glenmark Pharmaceuticals Limited |
| Type | Public Listed Global Pharmaceutical Company |
| Industry | Pharmaceuticals – Branded, Generics & OTC Drugs |
| Founded / Incorporated | 18 November 1977 |
| Founder | Gracias Saldanha |
| Headquarters | Mumbai, Maharashtra, India |
| MD & CEO | Glenn Saldanha |
| Core Business | Research-led development, manufacture & marketing of pharmaceuticals across branded, generics and OTC segments |
| Major Therapeutic Focus | Respiratory, Dermatology, Oncology, Cardiovascular, Diabetes, Immunology & Anti-infectives |
| Manufacturing & R&D | 11 world-class manufacturing facilities across 4 continents; 4 R&D centres |
| Area Served | 80+ countries globally, including India, North America & Europe |
| Employees | ~14,000+ globally |
| Stock Exchange Listing | BSE: 532296 & NSE: GLENMARK |
| CIN | L24299MH1977PLC019982 |
| Market Position | Ranked among the Top 100 biopharmaceuticals and Top 50 generics & biosimilars companies globally |
| Notable Developments | Licensing deal with AbbVie for oncology drug (ISB 2001) valued at ~$700 million upfront |
| Official Website | glenmarkpharma.com |
Net Worth and Market Cap
The market capitalization or net value of Glenmark Pharmaceuticals Ltd. is INR 560.34 billion. The enterprise value is 545.68 billion.
Corporate leadership
Founded in 1977, the corporation is headquartered in Mumbai, India. The company’s MD and chairman is Glenn Saldanha.
Overview of Services
In the therapeutic areas of dermatology, oncology, respiratory, immunology, pain management, central nervous system, hypertension, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective, the company offers branded, over-the-counter, and generic formulations in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, respiratory-metered dose inhalers, dry powder inhalers, and nasal sprays.
It develops, produces and markets a comprehensive range of branded, generic and over-the-counter medications spanning major treatment areas like respiratory, dermatology and oncology, and has presence in 80+ countries with various production units and R&D centres.
ISB 2001, a CD38 x BCMA x CD3 TREAT trispecific T cell engager in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 2301, an NK cell engager in preclinical trial for solid tumors; and GRC 65327, a Cbl-b inhibitor small molecule for solid tumors, are among its product pipeline.
The company’s pipeline also includes the telazorlimab OX40 antagonist antibody ISB 830-X8, which is in Phase 2 clinical trial for the treatment of atopic dermatitis, and the IL-1RAP antagonist monoclonal antibody ISB 880, which is in Phase 1 clinical trial for the treatment of hidradenitis suppurativa.
For the treatment of seasonal allergic rhinitis, the business also sells Ryaltris nasal spray.
Scale of Operations
Together with its affiliates, Glenmark Pharmaceuticals Limited develops, produces, and markets over-the-counter (OTC) pharmaceutical products, specialty medications, and generics in India, North America, Europe, and other countries. Glenmark operates in more than 80 nations.
